Pfizer withdraws its application to change the marketing authorisation for Viagra

The European Medicines Agency (EMEA)The European Medicines Agency (EMEA) has been formally notified by Pfizer Limited of its decision to withdraw its application for a change to the marketing authorisation for the medicine Viagra (sildenafil) 50 mg film-coated tablets. The change concerned switching the classification of the medicine from 'medicinal product subject to medical prescription' to 'medicinal product not subject to medical prescription' (an over-the-counter [OTC] medicine).

Viagra has been authorised in the European Union (EU) since 14 September 1998 for the treatment of men with erectile dysfunction. It is available on prescription as 25, 50 and 100 mg film-coated tablets. Viagra 50 mg was expected to be used for the same indication but without a prescription, as an OTC medicine.

The application for the change to the marketing authorisation for Viagra 50 mg was submitted to the EMEA on 8 November 2007. In its official letter, the company stated that the withdrawal is due to its wish to fully consider the comments from the Committee for Medicinal Products for Human Use (CHMP), recognising that there were some concerns regarding the proposed supply of Viagra 50 mg tablets without a prescription in the pharmacy setting across the EU.

More information about Viagra 50 mg for OTC use and the state of the scientific assessment at the time of the withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the EMEA website in due course.

Viagra 25, 50 and 100 mg film-coated tablets remain available as prescription-only medicines.

The European Public Assessment Report for Viagra is available at the EMEA website at http://www.emea.europa.eu/humandocs/Humans/EPAR/viagra/viagra.htm

For further information, please visit:
http://www.emea.europa.eu

Most Popular Now

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...